Pharsight

Onpattro patents expiration

ONPATTRO's oppositions filed in EPO
ONPATTRO Litigations
Can you believe ONPATTRO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8372968 ALNYLAM PHARMS INC RNA interference mediating small RNA molecules
Mar, 2021

(3 years ago)

US8895721 ALNYLAM PHARMS INC RNA interference mediating small RNA molecules
Mar, 2021

(3 years ago)

US9567582 ALNYLAM PHARMS INC RNA interference mediating small RNA molecules
Mar, 2021

(3 years ago)

US8552171 ALNYLAM PHARMS INC RNA sequence-specific mediators of RNA interference
Mar, 2021

(3 years ago)

US8895718 ALNYLAM PHARMS INC RNA interference mediating small RNA molecules
Mar, 2021

(3 years ago)

US8362231 ALNYLAM PHARMS INC RNA interference mediating small RNA molecules
Mar, 2021

(3 years ago)

US8334373 ALNYLAM PHARMS INC Nuclease resistant double-stranded ribonucleic acid
May, 2025

(1 year, 1 month from now)

US10240152 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(5 years from now)

US8168775 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(5 years from now)

US11079379 ALNYLAM PHARMS INC Methods of treating transthyretin (TTR) mediated amyloidosis
Aug, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9193753 ALNYLAM PHARMS INC RNA sequence-specific mediators of RNA interference
Mar, 2021

(3 years ago)

US8778902 ALNYLAM PHARMS INC RNA interference mediating small RNA molecules
Mar, 2021

(3 years ago)

US9943539 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
Nov, 2023

(5 months ago)

US9943538 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
Nov, 2023

(5 months ago)

US8642076 ALNYLAM PHARMS INC Lipid containing formulations
Oct, 2027

(3 years from now)

US8492359 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(4 years from now)

US11141378 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(4 years from now)

US8822668 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(4 years from now)

US8058069 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(4 years from now)

US9364435 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(4 years from now)

US9234196 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(5 years from now)

US8741866 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(5 years from now)

US8802644 ALNYLAM PHARMS INC Lipid formulation
Oct, 2030

(6 years from now)

US8158601 ALNYLAM PHARMS INC Lipid formulation
Nov, 2030

(6 years from now)

Onpattro is owned by Alnylam Pharms Inc.

Onpattro contains Patisiran Sodium.

Onpattro has a total of 24 drug patents out of which 10 drug patents have expired.

Expired drug patents of Onpattro are:

  • US9193753
  • US8778902
  • US9943539
  • US9943538
  • US8372968
  • US8895721
  • US9567582
  • US8552171
  • US8895718
  • US8362231

Onpattro was authorised for market use on 10 August, 2018.

Onpattro is available in solution;intravenous dosage forms.

Onpattro can be used as treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Drug patent challenges can be filed against Onpattro from 10 August, 2022.

The generics of Onpattro are possible to be released after 27 August, 2035.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-197) Aug 10, 2025
New Chemical Entity Exclusivity(NCE) Aug 10, 2023

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ONPATTRO family patents

Family Patents